Mongolia
Tuberculosis profile
Population  2012 2.8 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.2 (0.075–0.39) 7.2 (2.7–14)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.12 (0.1–0.14)
Prevalence  (includes HIV+TB) 11 (5.7–17) 380 (204–608)
Incidence  (includes HIV+TB) 6.2 (5.8–6.7) 223 (208–239)
Incidence (HIV+TB only) 0.011 (<0.01–0.011) 0.38 (0.35–0.41)
Case detection, all forms (%) 66 (62–71)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 1 716 (44) Relapse 184 (36)
Smear-negative 617 (16) Treatment after failure 54 (11)
Smear-unknown / not done 0 (0) Treatment after default 38 (7)
Extrapulmonary 1 611 (41) Other 233 (46)
Other 0 (0)      
Total new 3 944   Total retreatment 509  
           
Other (history unknown) 0        
Total new and relapse 4 128   Total cases notified 4 453  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.4 1.2 1.1
Age < 15 18 128 165
Laboratories 2012
Smear (per 100 000 population) 1.4
Culture (per 5 million population) 3.6
Drug susceptibility testing (per 5 million population) 1.8
Is second-line drug susceptibility testing available? Yes, in country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 86   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 94  
Retreatment 74  
TB/HIV 2012 Number (%)
TB patients with known HIV status 3 465 (78)
HIV-positive TB patients 4 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 3 (75)
HIV-positive TB patients on antiretroviral therapy (ART) 3 (75)
HIV-positive people screened for TB 105  
HIV-positive people provided with IPT 0  
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 1.4 (0.66–2.5) 26 (23–30)
MDR-TB cases among notified pulmonary
TB cases
33 (15–58) 130 (120–150)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 196 (11%) 681 (134%) 877
Laboratory-confirmed MDR-TB cases 32 178 210
Patients started on MDR-TB treatment     171
Financing TB control 2013
National TB programme budget (US$ millions) 8.2
% Funded domestically 66%
% Funded internationally 33%
% Unfunded <1%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-16 Data: www.who.int/tb/data